TransCode Therapeutics, Inc. entered into a Placement Agency Agreement with ThinkEquity LLC for a best efforts public offering of 10,000,000 shares of common stock at $0.30 per share, expected to close on July 24, 2024, with gross proceeds of $3.0 million.